98%
921
2 minutes
20
Purpose: Bronchiectasis is a chronic disease characterized by an irreversible dilatation of bronchi leading to chronic infection, airway inflammation, and progressive lung damage. Three specific patterns of bronchiectasis are distinguished in clinical practice: cylindrical, varicose, and cystic. The predominance and the extension of the type of bronchiectasis provide important clinical information. However, characterization is often challenging and is subject to high interobserver variability. The aim of this study is to provide an automatic tool for the detection and classification of bronchiectasis through convolutional neural networks.
Materials And Methods: Two distinct approaches were adopted: (i) direct network performing a multilabel classification of 32×32 regions of interest (ROIs) into 4 classes: healthy, cylindrical, cystic, and varicose and (ii) a 2-network serial approach, where the first network performed a binary classification between normal tissue and bronchiectasis and the second one classified the ROIs containing abnormal bronchi into one of the 3 bronchiectasis typologies. Performances of the networks were compared with other architectures presented in the literature.
Results: Computed tomography from healthy individuals (n=9, age=47±6, FEV1%pred=109±17, FVC%pred=116±17) and bronchiectasis patients (n=21, age=59±15, FEV1%pred=74±25, FVC%pred=91±22) were collected. A total of 19,059 manually selected ROIs were used for training and testing. The serial approach provided the best results with an accuracy and F1 score average of 0.84, respectively. Slightly lower performances were observed for the direct network (accuracy=0.81 and F1 score average=0.82). On the test set, cylindrical bronchiectasis was the subtype classified with highest accuracy, while most of the misclassifications were related to the varicose pattern, mainly to the cylindrical class.
Conclusion: The developed networks accurately detect and classify bronchiectasis disease, allowing to collect quantitative information regarding the radiologic severity and the topographical distribution of bronchiectasis subtype.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/RTI.0000000000000588 | DOI Listing |
Allergol Immunopathol (Madr)
September 2025
Department of Emergency Medicine, Tuzla State Hospital, İstanbul, Turkey.
Desensitization is an immunological process that creates temporary tolerance to a drug, which disappears once treatment is discontinued. Ciprofloxacin is a commonly used antibiotic, particularly for chronic lung diseases, yet there are very few desensitization protocols for it. Two ciprofloxacin desensitization schemes were developed a long time ago.
View Article and Find Full Text PDFCureus
August 2025
Thoracic Surgery, National Institute of Diseases of the Chest and Hospital, Dhaka, BGD.
Background: Pulmonary function testing, especially spirometry, is essential for assessing patients after pulmonary resection for tubercular and non-tubercular diseases. Tuberculosis (TB) remains a major cause of death globally, while other non-tubercular conditions such as lung abscess, bullous disease, and bronchiectasis also require lobectomy. This study aimed to compare late postoperative pulmonary function following lobectomy between TB and non-TB patients.
View Article and Find Full Text PDFCureus
August 2025
Pulmonology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Common variable immunodeficiency (CVID) is a rare immunodeficiency syndrome presenting with wide manifestations and leading to a delayed diagnosis. A 40-year-old male, a case of old treated tuberculosis, presented with a productive cough and hemoptysis. He had a history of recurrent respiratory symptoms previously attributed to post-tuberculosis sequelae with bilateral bronchiectasis, which can also occur as a manifestation of underlying common variable immunodeficiency (CVID).
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFCurr Opin Pulm Med
September 2025
Division of Infectious Diseases, Department of Medicine.
Purpose Of Review: Cystic fibrosis (CF) and non-CF bronchiectasis can predispose patients to airway infections that are difficult to treat. The purpose of this review is to discuss recently developed anti-infectives which show promise in treating these infections.
Recent Findings: The microbiology underlying respiratory tract infections in persons with CF (pwCF) and non-CF bronchiectasis is complex.